Therapeutic-dose heparin appears to benefit noncritically-ill COVID-19 patients, but it does not reduce deaths or other adverse endpoints compared with usual-care thromboprophylaxis if it’s initiated ...

Now reported in the Journal are the results of an international, multiplatform, randomized clinical trial that combined data from patients who were enrolled in one conventional randomized trial (ACTIV ...

Heparin-based thromboprophylaxis in obstetric patients did not reduce risk of venous thromboembolism (VTE), but may have increased the risks of other postpartum complications, a single-center ...

Please provide your email address to receive an email when new articles are posted on . Early administration of full-dose heparin slowed the thrombo-inflammatory process and reduced the risk for ...

Researchers moved one step closer to the ability to make heparin in cultured cells. Heparin is a potent anti-coagulant and the most prescribed drug in hospitals, yet cell-culture-based production of ...

Heparin, a widely available and affordable drug, has found to limit lung damage when inhaled by COVID-19 patients. The world-first findings by researchers from The Australian National University with ...

Lung cells put out a welcome mat for SARS-CoV-2, a welcome mat that has been equated with ACE2, a receptor molecule. But ACE2 may account for just half the mat, a new study indicates. The other half ...

A new method to analyse the blood thinning drug Heparin has been developed that can pinpoint contaminants more accurately and quickly, providing greater quality control and safety. A new method to ...

Heparin, the world's most widely used blood thinner, is used during procedures ranging from kidney dialysis to open heart surgery. Currently, heparin is derived from pig intestines, but scientists at ...

The Ohio biotechnology firm Optimvia Pharmaceuticals says it has developed a cost-effective synthetic method to produce large quantities of heparin, which is used to make a common blood thinner. And ...

New research reveals that patients receiving heparin therapy were diagnosed with Alzheimer's disease up to two years later, suggesting a possible protective effect of this common anticoagulant. Study: ...